Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases

Prostate

Volumn 73, Issue 9, 2013, Pages 932-940

  Larson, Sandy R ^a   Zhang, Xiaotun ^a   Dumpit, Ruth ^b   Coleman, Ilsa ^b   Lakely, Bryce ^a   Roudier, Martine ^c   Higano, Celestia S ^b,c   True, Lawrence D ^c   Lange, Paul H ^a,d   Montgomery, Bruce ^c   Corey, Eva ^a   Nelson, Peter S ^b,c   Vessella, Robert L ^a,d   Morrissey, Colm ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

bone; metastasis; osteoblastic; osteolytic; prostate cancer

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; DICKKOPF 1 PROTEIN; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GROWTH FACTOR; MACROPHAGE ELASTASE; OSTEOGENIC PROTEIN 1; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE KINASE 1; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 1; SUBSTANCE P; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EMU1; TRANSCRIPTION FACTOR NELL1; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 11B; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; AUTOPSY; BONE METASTASIS; BONE REMODELING; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; BONE REMODELING; ENDOTHELIN-1; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEOPLASM PROTEINS; OSTEOBLASTS; OSTEOLYSIS; PHOSPHOGLYCERATE KINASE; PROSTATIC NEOPLASMS; SUBSTANCE P;

EID: 84878327349     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22639     Document Type: Article

References (49)

1. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL,. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003; 34: 646-653.
2. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM,. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 2008; 180: 1154-1160.
3. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ,. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578-583.
4. Sturge J, Caley MP, Waxman J,. Bone metastasis in prostate cancer: Emerging therapeutic strategies. Nat Rev Clin Oncol 2011; 8: 357-368.
5. Lange PH, Vessella RL,. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 1998; 17: 331-336.
6. Roato I, D'Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De LA, Isaia G, Ferracini R,. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS ONE 2008; 3: e3627.
7. Rucci N, Teti A,. Osteomimicry: How tumor cells try to deceive the bone. Front Biosci (Schol Ed) 2010; 2: 907-915.
8. Koeneman KS, Yeung F, Chung LW,. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999; 39: 246-261.
9. Olson KB, Pienta KJ,. Pain management in patients with advanced prostate cancer. Oncology (Williston Park) 1999; 13: 1537-1549.
10. Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS, Vessella RL,. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration resistant prostate cancer: Results from the University of Washington rapid autopsy series. J Bone Miner Res 2012; [Epub ahead of print]. DOI: 10.1002/jbmr.1749
11. Yee AJ, Raje NS,. Denosumab a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging 2012; 7: 331-338.
12. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C,. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011; 377: 813-822.
13. Aghaloo T, Cowan CM, Zhang X, Freymiller E, Soo C, Wu B, Ting K, Zhang Z,. The effect of NELL1 and bone morphogenetic protein-2 on calvarial bone regeneration. J Oral Maxillofac Surg 2010; 68: 300-308.
14. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET,. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235-1244.
15. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR,. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 2005; 20: 2189-2199.
16. Jung Y, Shiozawa Y, Wang J, Wang J, Wang Z, Pedersen EA, Lee CH, Hall CL, Hogg PJ, Krebsbach PH, Keller ET, Taichman RS,. Expression of PGK1 by prostate cancer cells induces bone formation. Mol Cancer Res 2009; 7: 1595-1604.
17. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA,. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100: 10954-10959.
18. Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL, Keller ET, McCauley LK, Pinzone JJ, Rosol TJ,. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate 2011; 71: 615-625.
19. Hall CL, Kang S, MacDougald OA, Keller ET,. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 2006; 97: 661-672.
20. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ,. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 2008; 27: 5195-5203.
21. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH,. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 2007; 67: 6544-6548.
22. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW,. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1: 944-949.
23. Nelson J, Bagnato A, Battistini B, Nisen P,. The endothelin axis: Emerging role in cancer. Nat Rev Cancer 2003; 3: 110-116.
24. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA,. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006; 107: 289-298.
25. Zhang X, Zara J, Siu RK, Ting K, Soo C,. The role of NELL-1, a growth factor associated with craniosynostosis, in promoting bone regeneration. J Dent Res 2010; 89: 865-878.
26. Gkotzamanidou M, Dimopoulos MA, Kastritis E, Christoulas D, Moulopoulos LA, Terpos E,. Sclerostin: A possible target for the management of cancer-induced bone disease. Expert Opin Ther Targets 2012; 16: 761-769.
27. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ,. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 2011; 6: e25900.
28. Goto T, Nakao K, Gunjigake KK, Kido MA, Kobayashi S, Tanaka T,. Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors. Neuropeptides 2007; 41: 25-31.
29. Shih C, Bernard GW,. Neurogenic substance P stimulates osteogenesis in vitro. Peptides 1997; 18: 323-326.
30. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
31. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR,. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 2011; 6: e27970.
32. Spanjol J, Djordjevic G, Markic D, Klaric M, Fuckar D, Bobinac D,. Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: Immunohistochemical study. Coll Antropol 2010; 34 (Suppl 2): 119-125.
33. Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E,. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia 2010; 12: 192-205.
34. Bagnato A, Loizidou M, Pflug BR, Curwen J, Growcott J,. Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 2011; 163: 220-233.
35. Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, Wu-Wong JR, Ahmed T,. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000; 83: 360-365.
36. Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE,. Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone 2012; 51: 153-157.
37. Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET,. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008; 68: 1396-1404.
38. Casimiro S, Guise TA, Chirgwin J,. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009; 310: 71-81.
39. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D,. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010; 116: 1406-1418.
40. Itoh T, Ito Y, Ohtsuki Y, Ando M, Tsukamasa Y, Yamada N, Naoe T, Akao Y,. Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation. J Mol Histol 2012; 43 (5): 509-515. DOI: 10.1007/s10735-012-9415-1
41. Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Redini F,. RANKL/RANK/OPG: New therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004; 1704: 49-57.
42. Roudier M, Morrissey C, Huang L, Rohrbach K, Keller E, True L, Higano C, Vessella R, Dougall W,. Immunohistochemical detection in post-mortem specimens of RANK/RANKL/OPG in prostate cancer bone and soft tissue metastases. Am Soc Clin Oncol Prostate Cancer Symp 2007. http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=46&abstractID=20520
43. Leimeister C, Steidl C, Schumacher N, Erhard S, Gessler M,. Developmental expression and biochemical characterization of Emu family members. Dev Biol 2002; 249: 204-218.
44. Thiele S, Rauner M, Goettsch C, Rachner TD, Benad P, Fuessel S, Erdmann K, Hamann C, Baretton GB, Wirth MP, Jakob F, Hofbauer LC,. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem 2011; 112: 1593-1600.
45. Monroe DG, Gee-Lawrence ME, Oursler MJ, Westendorf JJ,. Update on Wnt signaling in bone cell biology and bone disease. Gene 2012; 492: 1-18.
46. Kerkela E, Bohling T, Herva R, Uria JA, Saarialho-Kere U,. Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation. Bone 2001; 29: 487-493.
47. Kerkela E, la-Aho R, Jeskanen L, Rechardt O, Grenman R, Shapiro SD, Kahari VM, Saarialho-Kere U,. Expression of human macrophage metalloelastase (MMP-12) by tumor cells in skin cancer. J Invest Dermatol 2000; 114: 1113-1119.
48. Pivetta E, Scapolan M, Pecolo M, Wassermann B, Abu-Rumeileh I, Balestreri L, Borsatti E, Tripodo C, Colombatti A, Spessotto P,. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. Breast Cancer Res 2011; 13: R105.
49. Nabha SM, dos Santos EB, Yamamoto HA, Belizi A, Dong Z, Meng H, Saliganan A, Sabbota A, Bonfil RD, Cher ML,. Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. Int J Cancer 2008; 122: 2482-2490.